Entheon Biomedical has announced that the first patient has been enrolled in the EBRX-101 study, a comprehensive phase I clinical trial evaluating the pharmacokinetics, pharmacodynamics and safety profile of N, N-dimethyltryptamine (DMT).
Category Press Release
Published in Biospace
Companies Featured
Entheon BiomedicalEntheon Biomedical is a listed (CSE) company that aims to develop DMT for addiction treatment.